Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorAnguita-Sánchez, Manuel
dc.contributor.authorSoriano Colomé, Toni
dc.contributor.authorNuñez Gil, Ivan Javier
dc.contributor.authorGomez Doblas, Juan Jose
dc.contributor.authorGonzalez-Juanatey, Carlos
dc.contributor.authorBarrios, Vivencio
dc.contributor.authorGarcia-Moll, Xavier
dc.date.accessioned2022-11-23T13:17:40Z
dc.date.available2022-11-23T13:17:40Z
dc.date.issued2022-10-11
dc.identifier.citationGonzález-Juanatey C, Anguita-Sánchez M, Barrios V, Núñez-Gil I, Gómez-Doblas JJ, García-Moll X, et al. Major Adverse Cardiovascular Events in Coronary Type 2 Diabetic Patients: Identification of Associated Factors Using Electronic Health Records and Natural Language Processing. J Clin Med. 2022 Oct 12;11(20):6004.
dc.identifier.issn2077-0383
dc.identifier.urihttps://hdl.handle.net/11351/8527
dc.descriptionDiabetes mellitus; Natural language processing; Risk factors
dc.description.abstractPatients with Type 2 diabetes mellitus (T2DM) and coronary artery disease (CAD) are at high risk of developing major adverse cardiovascular events (MACE). This is a multicenter, retrospective, and observational study performed in Spain aimed to characterize these patients in a real-world setting. Unstructured data from the Electronic Health Records were extracted by EHRead®, a technology based on Natural Language Processing and machine learning. The association between new MACE and the variables of interest were investigated by univariable and multivariable analyses. From a source population of 2,184,662 patients, we identified 4072 adults diagnosed with T2DM and CAD (62.2% male, mean age 70 ± 11). The main comorbidities observed included arterial hypertension, hyperlipidemia, and obesity, with metformin and statins being the treatments most frequently prescribed. MACE development was associated with multivessel (Hazard Ratio (HR) = 2.49) and single coronary vessel disease (HR = 1.71), transient ischemic attack (HR = 2.01), heart failure (HR = 1.32), insulin treatment (HR = 1.40), and percutaneous coronary intervention (PCI) (HR = 2.27), whilst statins (HR = 0.73) were associated with a lower risk of MACE occurrence. In conclusion, we found six risk factors associated with the development of MACE which were related with cardiovascular diseases and T2DM severity, and treatment with statins was identified as a protective factor for new MACE in this study.
dc.language.isoeng
dc.publisherMDPI
dc.relation.ispartofseriesJournal of Clinical Medicine;11(20)
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectMalalties coronàries - Factors de risc
dc.subjectDiabetis - Factors de risc
dc.subjectHistòries clíniques - Informàtica
dc.subject.meshElectronic Health Records
dc.subject.meshCoronary Artery Disease
dc.subject.meshDiabetes Mellitus
dc.titleMajor Adverse Cardiovascular Events in Coronary Type 2 Diabetic Patients: Identification of Associated Factors Using Electronic Health Records and Natural Language Processing
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.3390/jcm11206004
dc.subject.decshistorias clínicas electrónicas
dc.subject.decsenfermedad arterial coronaria
dc.subject.decsdiabetes mellitus
dc.relation.publishversionhttps://doi.org/10.3390/jcm11206004
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[González-Juanatey C] Hospital Universitario Lucus Augusti, Lugo, Spain. [Anguita-Sánchez M] Hospital Universitario Reina Sofía, Instituto Maimonides de Investigación Biomédica de Córdoba (IMIBIC), Universidad de Córdoba, Córdoba, Spain. [Barrios V] Hospital Universitario Ramón y Cajal, Madrid, Spain. [Núñez-Gil I] Hospital Clínico Universitario San Carlos, Madrid, Spain. [Gómez-Doblas JJ] Hospital Universitario Virgen de la Victoria CIBERCV (Centro de Investigación Biomédica en Red Enfermedades Cardiovasculares) and IBIMA (Instituto de Investigación Biomédica de Málaga), Málaga, Spain. [García-Moll X] Hospital Universitario Santa Creu i Sant Pau, Barcelona, Spain. [Soriano-Colomé T] Vall d’Hebron Hospital Universitari, Barcelona, Spain. CIBERCV, Barcelona, Spain
dc.identifier.pmid36294325
dc.identifier.wos000872820300001
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record